Evidence map›Paper›PMID 41515628›Full record

ArticleDiagnostics (Basel, Switzerland)2026

BacT-Seq, a Nanopore-Based Whole-Genome Sequencing Workflow Prototype for Rapid and Accurate Pathogen Identification and Resistance Prediction from Positive Blood Cultures: A Feasibility Study.

Meriem El Azami, Véronique Lanet, Corinne Beaulieu, Aurélien Griffon, Stéphane Schicklin, Pierre Mahé, Marion Darnaud, Marion Helsmoortel, Erwin Sentausa, Adrien Saliou and 5 more

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Meriem El AzamiBioMérieux SA, 69280 Marcy-l'Étoile, France.
Véronique LanetBioMérieux SA, 69280 Marcy-l'Étoile, France.
Corinne BeaulieuBioMérieux SA, 69280 Marcy-l'Étoile, France.
Aurélien GriffonBioMérieux SA, 69280 Marcy-l'Étoile, France.
Stéphane SchicklinBioMérieux SA, 69280 Marcy-l'Étoile, France.
Pierre MahéBioMérieux SA, 69280 Marcy-l'Étoile, France.
Marion DarnaudBIOASTER, Microbiology Research Institute, 69007 Lyon, France.ORCID 0000-0002-0919-8303
Marion HelsmoortelBIOASTER, Microbiology Research Institute, 69007 Lyon, France.ORCID 0000-0002-2702-5318
Erwin SentausaBIOASTER, Microbiology Research Institute, 69007 Lyon, France.ORCID 0000-0002-7377-351X
Adrien SaliouBIOASTER, Microbiology Research Institute, 69007 Lyon, France.
Mallory PonceletBIOASTER, Microbiology Research Institute, 69007 Lyon, France.
Raphaël FleuryUniversity Hospital Microbiology Laboratory, Hospices Civils de Lyon, 69004 Lyon, France.
Marine IbranosyanUniversity Hospital Microbiology Laboratory, Hospices Civils de Lyon, 69004 Lyon, France.
François VandeneschUniversity Hospital Microbiology Laboratory, Hospices Civils de Lyon, 69004 Lyon, France.
Emmanuelle Santiago-AllexantBioMérieux SA, 69280 Marcy-l'Étoile, France.

Funding

bioMérieux N/AFrench Government (Programme d'Investissements d'Avenir [PIA]) ANR-10AIRT-03
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antimicrobial resistance (AMR)antimicrobial susceptibility prediction (ASP)antimicrobial susceptibility testing (AST)bacteremiaBacT-Seq pipelineblood culturebloodstream infection (BSI)microbial identificationpathogen identificationwhole-genome sequencing

Identifiers

PMID41515628
PMCPMC12785933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.